Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 135.21 USD 0.16%
Market Cap: 21.4B USD
Have any thoughts about
Illumina Inc?
Write Note

Illumina Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Illumina Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Illumina Inc
NASDAQ:ILMN
Interest Income Expense
-$9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Interest Income Expense
-$310m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
0%
Danaher Corp
NYSE:DHR
Interest Income Expense
-$179m
CAGR 3-Years
N/A
CAGR 5-Years
-122%
CAGR 10-Years
-5%
Mettler-Toledo International Inc
NYSE:MTD
Interest Income Expense
-$76.4m
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-12%
Agilent Technologies Inc
NYSE:A
Interest Income Expense
-$6m
CAGR 3-Years
58%
CAGR 5-Years
33%
CAGR 10-Years
26%
IQVIA Holdings Inc
NYSE:IQV
Interest Income Expense
-$632m
CAGR 3-Years
-18%
CAGR 5-Years
-8%
CAGR 10-Years
-21%
No Stocks Found

Illumina Inc
Glance View

Market Cap
21.5B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.

ILMN Intrinsic Value
144.84 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Illumina Inc's Interest Income Expense?
Interest Income Expense
-9m USD

Based on the financial report for Sep 29, 2024, Illumina Inc's Interest Income Expense amounts to -9m USD.

What is Illumina Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
88%

Over the last year, the Interest Income Expense growth was 88%.

Back to Top